Doctors apparently opt out of suggesting generic versions of brand name drugs to their patients.

And the cost of this "oversight"? Probably in the tens of billions a year.

At least that's what researchers from Ohio State and (arch football rival) University of Michigan found when they studied the records of more than 100,000 patient from the 2010 to 2012 period.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.